Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Enterprise Value data on file, last reported at -$2.2 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$2.2 million, up 4.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 million (up 4.82% YoY), and the FY2025 annual result was -$2.1 million, up 66.63% from the prior year.
• Enterprise Value eased to -$2.2 million in Q1 2026 per VVOS's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$1.0 million in Q3 2023 and troughed at -$17.8 million in Q1 2022.
• A 5-year average of -$5.3 million and a median of -$3.9 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value soared 85.34% in 2022, then sank 531.1% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$3.5 million in 2022, then jumped by 53.31% to -$1.6 million in 2023, then sank by 281.01% to -$6.3 million in 2024, then jumped by 66.63% to -$2.1 million in 2025, then retreated by 6.7% to -$2.2 million in 2026.
• Business Quant data shows VVOS's Enterprise Value at -$2.2 million in Q1 2026, -$2.1 million in Q4 2025, and -$3.1 million in Q3 2025.